The metabolism of Olodaterol can be decreased when combined with Cyclosporine. Benoxaprofen may increase the nephrotoxic activities of Cyclosporine. Lumiracoxib may increase the nephrotoxic activities of Cyclosporine. The risk or severity of adverse effects can be increased when Methysergide is combined with Cyclosporine. The metabolism of Reboxetine can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Cyclosporine is combined with Gallopamil. The metabolism of Paramethadione can be decreased when combined with Cyclosporine. Tenoxicam may increase the nephrotoxic activities of Cyclosporine. Valsartan may increase the hyperkalemic activities of Cyclosporine. The serum concentration of Cyclosporine can be increased when it is combined with Dabigatran etexilate. The metabolism of Clonazepam can be decreased when combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Chloroxine. The metabolism of Chlorpromazine can be decreased when combined with Cyclosporine. The serum concentration of Ivacaftor can be increased when it is combined with Cyclosporine. The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cyclosporine. The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Cyclosporine. The serum concentration of Edoxaban can be increased when it is combined with Cyclosporine. Adapalene may increase the nephrotoxic activities of Cyclosporine. The metabolism of Venetoclax can be decreased when combined with Cyclosporine. Valrubicin may increase the nephrotoxic activities of Cyclosporine. Azilsartan medoxomil may increase the hyperkalemic activities of Cyclosporine. The risk or severity of adverse effects can be increased when Cyclosporine is combined with Bepridil. Olsalazine may increase the nephrotoxic activities of Cyclosporine. The metabolism of Norgestrel can be decreased when combined with Cyclosporine. The serum concentration of Cyclosporine can be increased when it is combined with Saquinavir. The metabolism of Trastuzumab emtansine can be decreased when combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Natamycin. The risk or severity of adverse effects can be increased when Cyclosporine is combined with Azelnidipine. Mefenamic acid may increase the nephrotoxic activities of Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Benzoic Acid. The metabolism of Levobupivacaine can be decreased when combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Itraconazole. The metabolism of Moclobemide can be decreased when combined with Cyclosporine. The serum concentration of Dofetilide can be increased when it is combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Sertaconazole. The metabolism of Clonidine can be decreased when combined with Cyclosporine. The serum concentration of Pazopanib can be increased when it is combined with Cyclosporine. Meloxicam may increase the nephrotoxic activities of Cyclosporine. The metabolism of Ethinyl Estradiol can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Cyclosporine is combined with Gabapentin. Droxicam may increase the nephrotoxic activities of Cyclosporine. The metabolism of Vincristine can be decreased when combined with Cyclosporine. The metabolism of Almotriptan can be decreased when combined with Cyclosporine. The metabolism of Podofilox can be decreased when combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Efinaconazole. The metabolism of Iloperidone can be decreased when combined with Cyclosporine. Pimecrolimus may increase the nephrotoxic activities of Cyclosporine. The metabolism of Rosiglitazone can be decreased when combined with Cyclosporine. The metabolism of Clotiazepam can be decreased when combined with Cyclosporine. The metabolism of Teniposide can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Cyclosporine is combined with Amrinone. The serum concentration of Cilostazol can be increased when it is combined with Cyclosporine. The serum concentration of Nintedanib can be increased when it is combined with Cyclosporine. The metabolism of Tiotropium can be decreased when combined with Cyclosporine. The metabolism of Sevoflurane can be decreased when combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Atomoxetine. The metabolism of Methoxyflurane can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Cyclosporine is combined with Flunarizine. The metabolism of Propofol can be decreased when combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Brefeldin A. The metabolism of Hydromorphone can be decreased when combined with Cyclosporine. The metabolism of Galantamine can be decreased when combined with Cyclosporine. The metabolism of Finasteride can be decreased when combined with Cyclosporine. The metabolism of Toremifene can be decreased when combined with Cyclosporine. The serum concentration of Colchicine can be increased when it is combined with Cyclosporine. The metabolism of Sertraline can be decreased when combined with Cyclosporine. The metabolism of Vandetanib can be decreased when combined with Cyclosporine. The serum concentration of Cisapride can be increased when it is combined with Cyclosporine. The metabolism of Estramustine can be decreased when combined with Cyclosporine. The metabolism of Udenafil can be decreased when combined with Cyclosporine. The metabolism of Mebendazole can be decreased when combined with Cyclosporine. The metabolism of Cephalexin can be decreased when combined with Cyclosporine. The metabolism of Sulfamoxole can be decreased when combined with Cyclosporine. Plazomicin may increase the nephrotoxic activities of Cyclosporine. Nandrolone may increase the hepatotoxic activities of Cyclosporine. The metabolism of Ixabepilone can be decreased when combined with Cyclosporine. Kanamycin may increase the nephrotoxic activities of Cyclosporine. The serum concentration of Digoxin can be increased when it is combined with Cyclosporine. The metabolism of Pergolide can be decreased when combined with Cyclosporine. The metabolism of Ethosuximide can be decreased when combined with Cyclosporine. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cyclosporine. Cyclosporine may increase the immunosuppressive activities of Fingolimod. The metabolism of Brigatinib can be decreased when combined with Cyclosporine. The serum concentration of Cyclosporine can be increased when it is combined with Crizotinib. The metabolism of Romidepsin can be decreased when combined with Cyclosporine. Sucralfate can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Alosetron can be decreased when combined with Cyclosporine. Didanosine can cause a decrease in the absorption of Cyclosporine resulting in a reduced serum concentration and potentially a decrease in efficacy. The metabolism of Trimethoprim can be decreased when combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Solithromycin. The metabolism of Dexlansoprazole can be decreased when combined with Cyclosporine. The metabolism of Ropinirole can be decreased when combined with Cyclosporine. The serum concentration of Bosentan can be increased when it is combined with Cyclosporine. The serum concentration of Cyclosporine can be increased when it is combined with Prinomastat. The metabolism of Dutasteride can be decreased when combined with Cyclosporine. Idarubicin may increase the nephrotoxic activities of Cyclosporine. The serum concentration of Rifaximin can be increased when it is combined with Cyclosporine. The metabolism of Cyclosporine can be increased when combined with Barbital. The serum concentration of Cyclosporine can be increased when it is combined with Letaxaban. The metabolism of Oxymorphone can be decreased when combined with Cyclosporine. The metabolism of Ethylmorphine can be decreased when combined with Cyclosporine. The metabolism of Asenapine can be decreased when combined with Cyclosporine. The serum concentration of Lomitapide can be increased when it is combined with Cyclosporine. The metabolism of Cyclosporine can be decreased when combined with Ketoconazole. The metabolism of Cyclosporine can be decreased when combined with Diltiazem. The serum concentration of Cyclosporine can be increased when it is combined with Fusidic Acid. Ribostamycin may increase the nephrotoxic activities of Cyclosporine. The metabolism of Bupropion can be decreased when combined with Cyclosporine. The metabolism of Selexipag can be decreased when combined with Cyclosporine. The metabolism of Safinamide can be decreased when combined with Cyclosporine. Cyclosporine may increase the neuromuscular blocking activities of Decamethonium. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Cyclosporine. The metabolism of Caffeine can be decreased when combined with Cyclosporine. The serum concentration of Cyclosporine can be increased when it is combined with Carvedilol. Indomethacin may increase the nephrotoxic activities of Cyclosporine. The serum concentration of Cyclosporine can be increased when it is combined with Racecadotril. The serum concentration of Cyclosporine can be increased when it is combined with Netupitant. The risk or severity of adverse effects can be increased when Cyclosporine is combined with Cinnarizine. The serum concentration of Cyclosporine can be increased when it is combined with Candoxatrilat. The metabolism of Cerivastatin can be decreased when combined with Cyclosporine. Cyclosporine may increase the neuromuscular blocking activities of Tubocurarine. Antipyrine may increase the nephrotoxic activities of Cyclosporine. The metabolism of Guanfacine can be decreased when combined with Cyclosporine. The metabolism of Conjugated estrogens can be decreased when combined with Cyclosporine. The metabolism of Escitalopram can be decreased when combined with Cyclosporine. The serum concentration of Halofantrine can be increased when it is combined with Cyclosporine. The metabolism of Albendazole can be decreased when combined with Cyclosporine. The serum concentration of Cyclosporine can be decreased when it is combined with Enzalutamide. The metabolism of Erlotinib can be decreased when combined with Cyclosporine. Seratrodast may increase the nephrotoxic activities of Cyclosporine.